# Pipeline

> Explore Peptone's small-molecule pipeline against intrinsically disordered proteins, with programs advancing from discovery toward the clinic.

[View this page on Peptone](https://peptone.io/pipeline/)

Small molecules against intrinsically disordered proteins, advancing from discovery toward the clinic

## One Product Engine, many disordered targets

Peptone's Product Engine generates small-molecule drug candidates against intrinsically disordered proteins. It measures protein dynamics, builds experimentally grounded ensemble models, designs binders against transient pockets, and returns candidates to the laboratory for biological validation across oncology, CNS disease, immunology and inflammation, and longevity.

## Partnering and Collaborations

Peptone actively partners with leading academic hospitals and research institutes to deepen mechanism-of-action understanding and disease biology for its compounds. The goal is first-in-class drug candidates built on access to cutting-edge models, patient-derived insight, and translational biology ahead of the field.

## Programs

- [AR-NTD antagonist](/pipeline/ar-ntd-antagonist.md) - AR-NTD; Metastatic castration-resistant prostate cancer; DC
- [c-Myc antagonist](/pipeline/cmyc.md) - c-Myc; MYC-driven solid tumors; Lead Optimization
- [TDP-43 aggregation modulator](/pipeline/tdp-43.md) - TDP-43; TDP-43 proteinopathy in ALS and frontotemporal dementia; Lead Optimization
- [Alpha-synuclein aggregation modulator](/pipeline/alpha-synuclein.md) - Alpha-synuclein; Parkinson's disease and related synucleinopathies; Hit to Lead
- [IRF-5 antagonist](/pipeline/irf-5.md) - IRF-5; Autoimmune and inflammatory disease, including systemic lupus erythematosus; Hit to Lead